Skip to main content
Signal8
Launch Terminal

SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc.

NASDAQ:SABSHealthcare
+3.72%$3.35
AH$3.35+0.00%vs close
Mkt Cap$304.8M
Float77.74M
O/S90.99M
Vol
$ Vol
RVOL
Inst Own75.2%
SI6.2%
Earnings
Dilution
SAB Biotherapeutics, Inc. logoNASDAQ:SABS$3.35+3.72%
FormDescription
25-NSE
SEC Filing
1
8-K
8.01,9.01
4
Statement of Changes in Beneficial Ownership
424B3
Prospectus
5
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
1
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
13G
Beneficial Ownership Report
13D/A
Beneficial Ownership Report (Active, Amended)
10-Q
Quarterly Report
8-K
7.01,9.01
4
Statement of Changes in Beneficial Ownership
8-K
5.07
13G/A
Beneficial Ownership Report (Amended)
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
10-Q
Quarterly Report
8-K
1.01,9.01
3
13G
Beneficial Ownership Report
DEF 14A
Definitive Proxy Statement
8-K
7.01,9.01
S-8
SEC Filing

1-25 of 432

…